|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionIL-17F is a 37kD homodimer of the IL-17 family and a signature Th17 marker. Of all the six IL-17 family members, IL-17F and IL-17A share the strongest homology (50% amino acid identity), and the two genes are located in the same chromosomal region. Recent studies have demonstrated coordinated regulation of IL-17A and IL-17F during Th17 differentiation. Expression of IL-17F and IL-17A has been detected in activated human peripheral blood lymphocytes, specifically by activated human CD4+ T cells. In addition to IL-17A, differentiated Th17 cells also produce IL-17F and IL-22 upon re-activation. Like IL-17A, IL-17F has been linked with inflammatory diseases. IL-17F and IL-17A expression has been observed in tissue samples from various autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, and asthma. IL-17F treatment of airway epithelium, vein endothelial cells, and fibroblasts has been reported to induce expression of IL-6, IL-8, GRO-α, ENA-78, TGF-β, MCP-1, G-CSF, GM-CSF, and ICAM-1. Like IL-17A, IL-17F is a disulfide-linked homodimeric glycoprotein. The IL-17F homodimer includes a classical cysteine knot motif, which is found also in the TGF-β, BMP, and NGF superfamilies. The presence of the cysteine knot motif suggested the possibility of a heterodimeric structure, as was reported for TGF-β and inhibin/activin. Recent reports confirm that co-expression of IL-17F and IL-17A in HEK293 cells results in the formation of biologically active IL-17F/IL-17A heterodimers, in addition to the IL-17F homodimers and IL-17A homodimers. Moreover, activated human CD4+ T cells were found to produce the IL-17A/F heterodimer, along with the corresponding homodimers. In comparing the relative potency of IL-17A, IL-17F, and IL-17A/F, all three were found to induce GRO-α secretion; IL-17A was most potent, followed by IL-17A/F heterodimer, then IL-17F (100fold lower than IL-17A). In the mouse, the IL-17A/F heterodimer (alone or in synergy with TNF-α) was found to regulate the expression of IL-6 and KC (mouse homolog of human GRO-α); this was found to be dependent on IL-17RA and TRAF6. Applications ReportedFor research use only, not for diagnostic or therapeutic use. Recombinant human IL-17F is biologically active and can promote IL-6 production in vitro. The recombinant human IL-17F is also useful as an ELISA standard. Applications TestedThe recombinant human IL-17F has been tested as the standard in a human IL-17F sandwich ELISA and in bioassay for induction of IL-6 production by NIH/3T3 cells. The ED50 is 500.0 ng/ml, corresponding to a specific activity of 2.0 x 10E3 Units/mg. References
Chang, S.H., et al. 2007. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. Advance online publication. 24 April 2007. doi: 10.1038. Wright, J.F., et al. 2007. Identification of an IL-17F/17A heterodimer in activated human CD4+ T cells. JBC. 282: 13447-13455. Liang, S.C., et al. 2006. IL-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of anti-microbial peptides. J. Exp. Med. 203: 2271-2279. Related ProductsCat. 88-7176 Human IL-17A (Interleukin-17A, IL17A) ELISA Ready-SET-Go! Cat. 12-7179 Phycoerythrin (PE) anti-human IL-17A (Interleukin-17A, IL17A) (clone eBio64DEC17) Cat. 88-7876 Human IL-17A (Interleukin-17A, IL17A) ELISPOT Ready-Set-Go! Cat. 34-8069 Carrier-Free Recombinant Human IL-6 (Interleukin-6, IL6) Cat. 34-8179 Carrier-Free Recombinant Human IL-17A (Interleukin-17A, IL17A) Cat. 34-8239 Carrier-Free Recombinant Human IL-23 (Interleukin-23, IL23) Cat. 34-8348 Carrier-Free Recombinant Human TGFb1 (Transforming Growth Factor beta 1, TGF-beta1, TGF-b1) |
||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |